CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
Sanborn RE, Hamid O, de Vries EG, et al. Journal for ImmunoTherapy of Cancer 2021;9:e002446. doi: 10.1136/jitc-2021-002446